Journal
CURRENT OPINION IN VIROLOGY
Volume 46, Issue -, Pages 1-8Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coviro.2020.07.011
Keywords
-
Categories
Funding
- Cancer Research Switzerland [KFS-4091-02-2017, KFS-4962-02-2020]
- KFSP-PrecisionMS of the University of Zurich
- HMZ ImmunoTargET of the University of Zurich
- Coronavirusfonds UZH
- Cancer Research Center Zurich
- Vontobel Foundation
- Baugarten Foundation
- Sobek Foundation
- Swiss Vaccine Research Institute
- Roche
- Novartis
- Swiss National Science Foundation [310030B_182827, CRSII5_180323]
Ask authors/readers for more resources
EBV is the most common human tumor virus, infecting over 95% of the adult population but only a small minority developing malignancies. The majority control EBV infection with specific lymphocytes, defining immune response characteristics. Current research focuses on developing immunotherapies against EBV and tumors.
Epstein Barr virus (EBV) is the most common human tumor virus, persistently infecting more than 95% of the human adult population and readily transforming human B cell in culture. Fortunately, only a small minority of EBV carriers develops virus associated malignancies. The majority controls persistent EBV infection with cytotoxic lymphocytes, mainly NK, gamma delta and CD8(+) T cells and the characteristics of the required immune responses get more and more defined by primary immunodeficiencies that affect molecules of these cytotoxic lymphocytes and their investigation in mice with reconstituted human immune system components (humanized mice) that are susceptible to EBV infection and associated lymphomagenesis. The gained information should be able to guide us to develop immunotherapies against EBV and tumors in general.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available